Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Enanta Pharmaceuticals seeks a Director of Toxicology to lead nonclinical safety strategies across discovery and development. The role includes oversight of internal teams, CROs, and external partners, shaping regulatory outputs and risk management.
You will guide cross-functional programs, influence strategic investments, and build a high-performing team with emphasis on GLP/non-GLP studies and global regulatory interactions (FDA/EMA/ICH).
The Director of Toxicology will lead a critical scientific area responsible for toxicology and safety pharmacology activities supporting Enanta’s discovery and development portfolio. This individual will develop and execute nonclinical safety strategies, lead internal and external teams, and ensure delivery of high-quality scientific and regulatory outputs across multiple programs.
The Director will influence scientific strategy and investment decisions, translate portfolio priorities into operational plans, and drive achievement of critical milestones. Working cross-functionally with research, clinical development, regulatory affairs, CMC, and external partners, this individual will provide strategic guidance, identify and mitigate safety risks, and ensure alignment on priorities, resources, timelines, and key decisions.
The position may be filled at the Director or Senior Director level based on the selected candidate’s experience, leadership scope, and demonstrated ability to influence scientific and organizational strategy.
At Enanta Pharmaceuticals, you will be part of a team working on projects and programs that truly matter. We offer a supportive, inclusive environment where innovation is not just encouraged but celebrated. You’ll have the opportunity to grow, collaborate, and make a tangible impact.
Enanta is committed to providing compensation transparency. The expected base salary range for this position is $173,000 to $250,000, based on experience, qualifications, and market conditions. Offers will be determined by several factors, including individual experience and expertise, ensuring both equity and competitiveness.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier‑stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
Enanta Pharmaceuticals is an equal opportunity employer (EOE) with a commitment to diversity.
All individuals, regardless of personal characteristics, are encouraged to apply. All qualified applicants will receive consideration for employment without regard to race, color, national origin, age, religious creed, gender, gender identity, sexual orientation, physical or mental disability, protected veteran status, or any other class protected by law.